Open AccessRidinilazole: a novel antimicrobial for Clostridium difficile infection
Author(s) -
Jonathan Cho
Publication year - 2018
Publication title -
annals of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.886
H-Index - 33
eISSN - 1792-7463
pISSN - 1108-7471
DOI - 10.20524/aog.2018.0336
Subject(s) - clostridium difficile , medicine , vancomycin , nausea , adverse effect , antimicrobial , collateral damage , intensive care medicine , abdominal pain , antibiotics , microbiology and biotechnology , bacteria , staphylococcus aureus , biology , genetics , criminology , sociology
Clostridium difficile ( C. difficile ) infection remains a global healthcare threat worldwide and the limited options available for its treatment are of particular concern. Ridinilazole is one potential future agent, as it demonstrates rapid bactericidal activity against C. difficile . Current studies show that ridinilazole has a lower propensity for collateral damage to the gut microbiome and appears to diminish the production of C. difficile toxins. Results from phase II studies demonstrate that patients receiving ridinilazole had a higher sustained clinical response compared with patients receiving vancomycin (66.7% vs. 42.4%; P=0.0004). Adverse reactions were similar between ridinilazole and vancomycin (40% vs. 56%, respectively), with most being gastrointestinal-related. Nausea (20%) and abdominal pain (12%) were the most commonly reported adverse reactions associated with ridinilazole. Phase II study results are promising and future availability of phase III trial results will help further delineate the role and value of ridinilazole.